Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 73Pancreatic Neoplasms 44Neoplasms 27Neoplasm Metastasis 25Head and Neck Neoplasms 23Brain Neoplasms 21Breast Neoplasms 18Glioblastoma 15Adenocarcinoma of Lung 15Squamous Cell Carcinoma of Head and Neck 14Gliosarcoma 14Adenocarcinoma, Bronchiolo-Alveolar 11Colorectal Neoplasms 10Glioma 9Carcinoma, Squamous Cell 8Carcinoma, Hepatocellular 8Adenocarcinoma 7Rectal Neoplasms 6Prostatic Neoplasms 6Esophageal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Astrocytoma 6Oligodendroglioma 5Liver Neoplasms 5Colonic Neoplasms 5Carcinoma 5Recurrence 4Ovarian Neoplasms 4

Interventions

Cisplatin 20Surgical Procedures, Operative 9Docetaxel 8Cetuximab 8Radiotherapy, Intensity-Modulated 7Magnetic Resonance Spectroscopy 6pembrolizumab 5Specimen Handling 5Radiotherapy 5Fluorouracil 5toripalimab 4Surveys and Questionnaires 4Radiation 4Paclitaxel 4Chemoradiotherapy 4Celecoxib 4X-Rays 3Platinum 3Counseling 3Carboplatin 3130-nm albumin-bound paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3camrelizumab 2Taxes 2Standard of Care 2Psychiatric Rehabilitation 2Practice Guidelines as Topic 2Neoadjuvant Therapy 2Narrow Band Imaging 2Interviews as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hypopharyngeal Neoplasms × Erlotinib Hydrochloride × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡